Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its audited results for the year ended 31 December 2023.
Financial & Corporate Highlights
· Cash balance of £12.2 million as at 31 December 2023
· Industry veteran, Professor Brendan Buckley, appointed as Non-Executive Director
· Recruitment of key management hires, former executives of Amryt Pharma plc, a rare disease company that was acquired by Chiesi Farmaceutica for US$1.48 billion